| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925264 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US10765640 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11278623 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11786455 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9283174 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US10765749 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US9931403 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(7 years from now) | |
| US11793766 | SCILEX PHARMS | Non-aqueous patch for the relief of pain |
May, 2031
(7 years from now) | |
Ztlido is owned by Scilex Pharms.
Ztlido contains Lidocaine.
Ztlido has a total of 8 drug patents out of which 0 drug patents have expired.
Ztlido was authorised for market use on 28 February, 2018.
Ztlido is available in patch;topical dosage forms.
Ztlido can be used as method for relieving the pain associated with post-herpetic neuralgia.
The generics of Ztlido are possible to be released after 10 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 28, 2021 |
Drugs and Companies using LIDOCAINE ingredient
Market Authorisation Date: 28 February, 2018
Treatment: Method for relieving the pain associated with post-herpetic neuralgia
Dosage: PATCH;TOPICAL
ZTLIDO family patents
